Peripheral Biomarkers for First-Episode Psychosis—Opportunities from the Neuroinflammatory Hypothesis of Schizophrenia

키워드

참고문헌 (122)

1. McGrath J, "Schizophrenia : a concise overview of incidence, prevalence, and mortality", Epidemiol Rev, 30, pp.67~76 (2008)
2. Nordstroem AL, "Burden of illness of people with persistent symptoms of schizophrenia : a multinational cross-sectional study", Int J Soc Psychiatry, 63, pp.139~150 (2017)
3. Fusar-Poli P, "The psychosis high-risk state : a comprehensive state-of-the-art review", JAMA Psychiatry, 70, pp.107~120 (2013)
4. Henry LP, "The EPPIC follow-up study of first-episode psychosis : longerterm clinical and functional outcome 7 years after index admission", J Clin Psychiatry, 71, pp.716~728 (2010)
5. Schultze-Lutter F, "EPA guidance on the early detection of clinical high risk states of psychoses", Eur Psychiatry, 30, pp.405~416 (2015)
6. Schmitt A, "Consensus paper of the WFSBP Task Force on Biological Markers : Criteria for biomarkers and endophenotypes of schizophrenia part II : Cognition, neuroimaging and genetics", World J Biol Psychiatry, 17, pp.406~428 (2016)
7. Sun XY, "Aberrant microRNA expression in peripheral plasma and mononuclear cells as specific blood-based biomarkers in schizophrenia patients", J Clin Neurosci, 22, pp.570~574 (2015)
8. Schmitt A, "Consensus paper of the WFSBP Task Force on Biological Markers : Criteria for biomarkers and endophenotypes of schizophrenia, part III : Molecular mechanisms", World J Biol Psychiatry, 18, pp.330~356 (2017)
9. Chan MK, "Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset", Transl Psychiatry, 5, pp.e601~ (2015)
10. Schwarz E, "Identification of a biological signature for schizophrenia in serum", Mol Psychiatry, 17, pp.494~502 (2012)
11. Sabherwal S, "Blood biomarker discovery in drug-free schizophrenia : the contributionof proteomics and multiplex immunoassays", Expert Rev Proteomics, 13, pp.1141~1155 (2016)
12. Rodrigues-Amorim D, "Schizophrenia : a review of potential biomarkers", J Psychiatr Res, 93, pp.37~49 (2017)
13. Martins-de-Souza D, "Proteomics and Metabolomics in Psychiatry" (2014), Karger
14. Harrison PJ, "The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications", Psychopharmacology (Berl), 174, pp.151~162 (2004)
15. Chana G, "Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis", Front Cell Neurosci, 7, pp.95~ (2013)
16. Doorduin J, "Neuroinflammation in schizophrenia-related psychosis : a PET study", J Nucl Med, 50, pp.1801~1807 (2009)
17. Koutsouleris N, "Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers", Brain, 138, pp.2059~2073 (2015)
18. Thibaut F, "Consensus paper of the WFSBP Task Force on Biological Markers : criteria for biomarkers and endophenotypes of schizophrenia part I : Neurophysiology", World J Biol Psychiatry, 16, pp.280~290 (2015)
19. Watkins CC, "Clinical studies of neuroinflammatory mechanisms in schizophrenia", Schizophr Res, 176, pp.14~22 (2016)
20. Muller N, "The role of inflammation in schizophrenia", Front Neurosci, 9, pp.372~ (2015)
21. Khandaker GM, "Inflammation and immunity in schizophrenia : implications for pathophysiology and treatment", Lancet Psychiatry, 2, pp.258~270 (2015)
22. Meyer U, "Developmental neuroinflammation and schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 42, pp.20~34 (2013)
23. Anderson G, "Schizophrenia : linking prenatal infection to cytokines, the tryptophan catabolite(TRYCAT)pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression", Prog Neuropsychopharmacol Biol Psychiatry, 42, pp.5~19 (2013)
24. Tomasik J, "Neuroimmune biomarkers in schizophrenia", Schizophr Res, 176, pp.3~13 (2016)
25. Fond G, "The promise of biological markers for treatment response in first-episode psychosis : a systematic review", Schizophr Bull, 41, pp.559~573 (2015)
26. Mondelli V, "Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis", Schizophr Bull, 41, pp.1162~1170 (2015)
27. Yung AR, "Mapping the onset of psychosis : the Comprehensive Assessment of At-Risk Mental States", Aust N Z J Psychiatry, 39, pp.964~971 (2005)
28. Gaughran F, "Soluble interleukin 2 receptor levels in families of people with schizophrenia", Schizophr Res, 56, pp.235~239 (2002)
29. Lizano PL, "Angiogenic and immune signatures in plasma of young relatives at familial high-risk for psychosis and first-episode patients : a preliminary study", Schizophr Res, 170, pp.115~122 (2016)
30. Zeni-Graiff M, "Peripheral immuno-inflammatory abnormalities in ultra-high risk of developing psychosis", Schizophr Res, 176, pp.191~195 (2016)
31. Hayes LN, "Inflammatory molecular signature associated with infectious agents in psychosis", Schizophr Bull, 40, pp.963~972 (2014)
32. Khoury R, "Inflammatory biomarkers in individuals at clinical high risk for psychosis (CHR-P): State or trait?", Schizophr Res, 199, pp.31~38 (2018)
33. Miller BJ, "Meta-analysis of cytokine alterations in schizophrenia : clinical status and antipsychotic effects", Biol Psychiatry, 70, pp.663~671 (2011)
34. de Witte L, "Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment", Schizophr Res, 154, pp.23~29 (2014)
35. Goldsmith DR, "A meta-analysis of blood cytokine network alterations in psychiatric patients : comparisons between schizophrenia, bipolar disorder and depression", Mol Psychiatry, 21, pp.1696~1709 (2016)
36. Upthegrove R, "Cytokine function in medication-naive first episode psychosis : a systematic review and meta-analysis", Schizophr Res, 155, pp.101~108 (2014)
37. Song X, "Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naive, first-episode schizophrenia", Psychopharmacology(Berl), 231, pp.319~325 (2014)
38. Di Nicola M, "Serum and gene expression profile of cytokines in first-episode psychosis", Brain Behav Immun, 31, pp.90~95 (2013)
39. Borovcanin M, "Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse", J Psychiatr Res, 46, pp.1421~1426 (2012)
40. Karanikas E, "Cytokines, cortisol and IGF-1 in first episode psychosis and ultra high risk males. Evidence for TNF-alpha, IFN-gamma, TauNFbeta, IL-4 deviation", Asian J Psychiatr, 26, pp.99~103 (2017)
41. Noto C, "Effects of depression on the cytokine profile in drug naive first-episode psychosis", Schizophr Res, 164, pp.53~58 (2015)
42. Noto C, "Effects of risperidone on cytokine profile in drug-naive first-episode psychosis", Int J Neuropsychopharmacol, 18 (2014)
43. Borovcanin M, "Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia", Psychoneuroendocrinology, 56, pp.143~147 (2015)
44. Hong W, "Higher plasma S100B concentrations in schizophrenia patients, and dependently associated with inflammatory markers", Sci Rep, 6, pp.27584~ (2016)
45. Deng H, "Elevated plasma S100B, psychotic symptoms, and cognition in schizophrenia", Psychiatr Q, 89, pp.53~60 (2018)
46. Zhang XY, "Increased serum S100B in never-medicated and medicated schizophrenic patients", J Psychiatr Res, 44, pp.1236~1240 (2010)
47. Li Y, "Osteopontin is a blood biomarker for microglial activation and brain injury in experimental hypoxic-ischemic encephalopathy", eNeuro, 4 (2017)
48. Erhardt S, "Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia", Neurosci Lett, 313, pp.96~98 (2001)
49. Erhardt S, "Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid", Acta Physiol Scand, 175, pp.45~53 (2002)
50. Joaquim HPG, "Kynurenine is correlated with IL-1beta in plasma of schizophrenia patients", J Neural Transm(Vienna), 125, pp.869~873 (2018)
51. Condray R, "3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia", Int J Neuropsychopharmacol, 14, pp.756~767 (2011)
52. Plitman E, "Kynurenic Acid in Schizophrenia : A Systematic Review and Meta-analysis", Schizophr Bull, 43, pp.764~777 (2017)
53. Myint AM, "Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients", Brain Behav Immun, 25, pp.1576~1581 (2011)
54. Smith RS, "A comprehensive macrophage-T-lymphocyte theory of schizophrenia", Med Hypotheses, 39, pp.248~257 (1992)
55. Tsay CJ, "Julius Wagner-Jauregg and the legacy of malarial therapy for the treatment of general paresis of the insane", Yale J Biol Med, 86, pp.245~254 (2013)
56. Buka SL, "Maternal infections and subsequent psychosis among offspring", Arch Gen Psychiatry, 58, pp.1032~1037 (2001)
57. Brown AS, "Serologic evidence of prenatal influenza in the etiology of schizophrenia", Arch Gen Psychiatry, 61, pp.774~780 (2004)
58. Brown AS, "Prenatal infection as a risk factor for schizophrenia", Schizophr Bull, 32, pp.200~202 (2006)
59. Brown AS, "Prenatal infection and schizophrenia : a review of epidemiologic and translational studies", Am J Psychiatry, 167, pp.261~280 (2010)
60. Brown AS, "The risk for schizophrenia from childhood and adult infections", Am J Psychiatry, 165, pp.7~10 (2008)
61. Zubin J, "Vulnerability--a new view of schizophrenia", J Abnorm Psychol, 86, pp.103~126 (1977)
62. Keshavan MS, "Development, disease and degeneration in schizophrenia : a unitary pathophysiological model", J Psychiatr Res, 33, pp.513~521 (1999)
63. Murray RM, "Is schizophrenia a neurodevelopmental disorder?", Br Med J (Clin Res Ed), 295, pp.681~682 (1987)
64. Prata J, "Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers-pre-clinical and clinical investigations", J Neuroinflammation, 14, pp.179~ (2017)
65. Drexhage RC, "An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro-and anti-inflammatory forces", Int J Neuropsychopharmacol, 14, pp.746~755 (2011)
66. Altamura AC, "Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology", Prog Neuropsychopharmacol Biol Psychiatry, 42, pp.63~70 (2013)
67. Na KS, "The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 48, pp.277~286 (2014)
68. Eaton WW, "Association of schizophrenia and autoimmune diseases : linkage of Danish national registers", Am J Psychiatry, 163, pp.521~528 (2006)
69. Khandaker GM, "A population-based study of atopic disorders and inflammatory markers in childhood before psychotic experiences in adolescence", Schizophr Res, 152, pp.139~145 (2014)
70. Kayser MS, "Anti-NMDA receptor encephalitis, autoimmunity, and psychosis", Schizophr Res, 176, pp.36~40 (2016)
71. antibodies in patients with schizophrenia and related psychoses : a systematic review and meta-analysis, "Psychol Med", 2014, 2475~2487
72. Lennox BR, "Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis : a case-control study", Lancet Psychiatry, 4, pp.42~48 (2017)
73. "Schizophrenia Working Group of the Psychiatric Genomics C Biological insights from 108 schizophrenia-associated genetic loci", Nature, 511, pp.421~427 (2014)
74. Stefansson H, "Common variants conferring risk of schizophrenia", Nature, 460, pp.744~747 (2009)
75. Jeffries CD, "Insights into psychosis risk from leukocyte microRNA expression", Transl Psychiatry, 6, pp.e981~ (2016)
76. Liu S, "Diagnostic value of blood-derived microRNAs for schizophrenia : results of a meta-analysis and validation", Sci Rep, 7, pp.15328~ (2017)
77. Clarke MC, "Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia", Am J Psychiatry, 166, pp.1025~1030 (2009)
78. Yao JK, "Antioxidants, redox signaling, and pathophysiology in schizophrenia : an integrative view", Antioxid Redox Signal, 15, pp.2011~2035 (2011)
79. Sawa A, "Oxidative stress and inflammation in schizophrenia", Schizophr Res, 176, pp.1~2 (2016)
80. Shovestul BJ, "Pilot study examining the relationship of childhood trauma, perceived stress, and medication use to serum kynurenic acid and kynurenine levels in schizophrenia", Schizophr Res, 185, pp.200~201 (2017)
81. Phillips LJ, "Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis : implications for the development of psychotic disorders", Aust N Z J Psychiatry, 40, pp.725~741 (2006)
82. Garcia-Bueno B, "Stress as a neuroinflammatory condition in brain : damaging and protective mechanisms", Neurosci Biobehav Rev, 32, pp.1136~1151 (2008)
83. Frank MG, "Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses", Brain Behav Immun, 21, pp.47~59 (2007)
84. Di Forti M, "Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis : a case-control study", Lancet Psychiatry, 2, pp.233~238 (2015)
85. Niemi-Pynttari JA, "Substance-induced psychoses converting into schizophrenia : a register-based study of 18, 478 Finnish inpatient cases", J Clin Psychiatry, 74, pp.e94~e99 (2013)
86. Hill MN, "Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis", Neuropsychopharmacology, 34, pp.2733~2745 (2009)
87. Muller N, "Anti-inflammatory treatment in schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 42, pp.146~153 (2013)
88. Koola MM, "Can anti-inflammatory medications improve symptoms and reduce mortality in schizophrenia?", Curr Psychiatr, 15, pp.52~57 (2016)
89. Marini S, "Celecoxib adjunctive treatment to antipsychotics in schizophrenia : a review of randomized clinical add-on trials", Mediators Inflamm, 2016, pp.3476240~ (2016)
90. Fillman SG, "Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder", Transl Psychiatry, 4, pp.e365~ (2014)
91. Altamura AC, "Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder : comparison with schizophrenia", Psychiatry Clin Neurosci, 68, pp.21~36 (2014)
92. Regen F, "Neuroinflammation and alzheimer's disease : implications for microglial activation", Curr Alzheimer Res, 14, pp.1140~1148 (2017)
93. Careaga M, "Maternal immune activation and autism spectrum disorder : from rodents to nonhuman and human primates", Biol Psychiatry, 81, pp.391~401 (2017)
94. Haroon E, "Inflammation, glutamate, and glia : a trio of trouble in mood disorders", Neuropsychopharmacology, 42, pp.193~215 (2017)
95. Deverman BE, "Cytokines and CNS development", Neuron, 64, pp.61~78 (2009)
96. Monje ML, "Inflammatory blockade restores adult hippocampal neurogenesis", Science, 302, pp.1760~1765 (2003)
97. Garver DL, "Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype", Neuropsychopharmacology, 28, pp.1515~1520 (2003)
98. Prasad KM, "Differential susceptibility of white matter tracts to inflammatory mediators in schizophrenia : an integrated DTI study", Schizophr Res, 161, pp.119~125 (2015)
99. Ellman LM, "Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8", Schizophr Res, 121, pp.46~54 (2010)
100. Khandaker GM, "Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life : a population-based longitudinal study", JAMA Psychiatry, 71, pp.1121~1128 (2014)
101. Stojanovic A, "Increased serum interleukin-6 levels in early stages of psychosis : associations with at-risk mental states and the severity of psychotic symptoms", Psychoneuroendocrinology, 41, pp.23~32 (2014)
102. Banks WA, "The blood-brain barrier in psychoneuroimmunology", Neurol Clin, 24, pp.413~419 (2006)
103. Buka SL, "Maternal cytokine levels during pregnancy and adult psychosis", Brain Behav Immun, 15, pp.411~420 (2001)
104. Brown AS, "Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring", Am J Psychiatry, 161, pp.889~895 (2004)
105. Potvin S, "Inflammatory cytokine alterations in schizophrenia : a systematic quantitative review", Biol Psychiatry, 63, pp.801~808 (2008)
106. Al-Hakeim HK, "IL-6, IL-18, sIL-2R, and TNFalpha proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation", J Affect Disord, 182, pp.106~114 (2015)
107. Al-Asmari AK, "Inflammation and schizophrenia : alterations in cytokine levels and perturbation in antioxidative defense systems", Hum Exp Toxicol, 33, pp.115~122 (2014)
108. Baker I, "Serum cytokine concentrations in patients with schizophrenia", Schizophr Res, 20, pp.199~203 (1996)
109. Simsek S, "Serum IL-4 and IL-10 Levels correlate with the symptoms of the drug-naive adolescents with first episode, early onset schizophrenia", J Child Adolesc Psychopharmacol, 26, pp.721~726 (2016)
110. Monji A, "Neuroinflammation in schizophrenia especially focused on the role of microglia", Prog Neuropsychopharmacol Biol Psychiatry, 42, pp.115~121 (2013)
111. Garcia-Alvarez L, "Differential blood-based biomarkers of psychopathological dimensions of schizophrenia", Rev Psiquiatr Salud Ment, 9, pp.219~227 (2016)
112. Sparkman NL, "Neuroinflammation associated with aging sensitizes the brain to the effects of infection or stress", Neuroimmunomodulation, 15, pp.323~330 (2008)
113. Steiner J, "Immunological aspects in the neurobiology of suicide : elevated microglial density in schizophrenia and depression is associated with suicide", J Psychiatr Res, 42, pp.151~157 (2008)
114. Howes OD, "Inflammation and the neural diathesisstress hypothesis of schizophrenia: a reconceptualization", Transl Psychiatry, 7, pp.e1024~ (2017)
115. Block ML, "Microglia-mediated neurotoxicity : uncovering the molecular mechanisms", Nat Rev Neurosci, 8, pp.57~69 (2007)
116. Giriko CA, "Delayed physical and neurobehavioral development and increased aggressive and depression-like behaviors in the rat offspring of dams fed a high-fat diet", Int J Dev Neurosci, 31, pp.731~739 (2013)
117. Baldwin P, "Epidemiology of first-episode psychosis : illustrating the challenges across diagnostic boundaries through the Cavan-Monaghan study at 8 years", Schizophr Bull, 31, pp.624~638 (2005)
118. Banerjee J, "Regulation of GABAergic inputs to CA1 pyramidal neurons by nicotinic receptors and kynurenic acid", J Pharmacol Exp Ther, 341, pp.500~509 (2012)
119. Kegel ME, "Imbalanced kynurenine pathway in schizophrenia", Int J Tryptophan Res, 7, pp.15~22 (2014)
120. de la Fuente-Sandoval C, "Cortico-striatal GABAergic and glutamatergic dysregulations in subjects at ultra-high risk for psychosis investigated with proton magnetic resonance spectroscopy", Int J Neuropsychopharmacol, 19, pp.pyv105~ (2015)
121. Cohen SM, "The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia", Schizophr Res, 167, pp.98~107 (2015)
122. Linderholm KR, "Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia", Schizophr Bull, 38, pp.426~432 (2012)

관련 논문AI추천